{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:06:37Z","timestamp":1775829997013,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Omadacycline, an aminomethylcycline, is a novel member of the tetracycline class of antibiotics. It has received approval by the US Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, and is available in both oral and intravenous formulations. It is also being evaluated in clinical trials for the treatment of cystitis and pyelonephritis. The omadacycline molecule was designed to overcome tetracycline resistance and has broad-spectrum activity that includes gram-positive bacteria, gram-negative bacteria, anaerobes, atypicals, and other drug-resistant strains, like methicillin-resistant Staphylococcus aureus, as well as Yersinia pestis and Bacillus anthracis, organisms of biodefense interest. Omadacycline has minimal drug-drug pharmacokinetic interactions and a favorable safety profile, with the most common adverse events being gastrointestinal symptoms.<\/jats:p>","DOI":"10.1093\/cid\/ciz242","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T21:06:36Z","timestamp":1553029596000},"page":"890-896","source":"Crossref","is-referenced-by-count":35,"title":["Omadacycline: A Novel Tetracycline Derivative With Oral and Intravenous Formulations"],"prefix":"10.1093","volume":"69","author":[{"given":"Richard R","family":"Watkins","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Cleveland Clinic Akron General, Akron"},{"name":"Department of Medicine, Northeast Ohio Medical University, Rootstown"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stan","family":"Deresinski","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,20]]},"reference":[{"key":"2019081601553266800_CIT0001","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1128\/AAC.01536-15","article-title":"Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline","volume":"59","author":"Honeyman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0002","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","article-title":"Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic","volume":"24","author":"Tanaka","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"2019081601553266800_CIT0003","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.3390\/antibiotics5040032","article-title":"The novel aminomethylcycline omadacycline has high specificity for the primary tetracycline-binding site on the bacterial ribosome","volume":"5","author":"Heidrich","year":"2016","journal-title":"Antibiotics"},{"key":"2019081601553266800_CIT0004","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02434-16","article-title":"In vitro and in vivo activity of omadacycline against two biothreat pathogens, Bacillus anthracis and Yersinia pestis","volume":"61","author":"Steenbergen","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0005","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","article-title":"Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections","volume":"11","author":"Villano","year":"2016","journal-title":"Future Microbiol"},{"key":"2019081601553266800_CIT0006","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY antimicrobial surveillance program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0007","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1128\/AAC.01734-16","article-title":"In vitro activities of omadacycline (PTK 0796) and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"60","author":"Waites","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00047-18","article-title":"In vitro activities of omadacycline and comparators against anaerobic bacteria","volume":"62","author":"Stapert","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02551-17","article-title":"Comparative in vitro activity of omadacycline against dog and cat bite wound isolates","volume":"62","author":"Goldstein","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0010","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1128\/AAC.00743-12","article-title":"In vitro activity of TP-271 against Mycobacterium abscessus, Mycobacterium fortuitum, and Nocardia species","volume":"56","author":"Cynamon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0011","doi-asserted-by":"crossref","unstructured":"Schoen C , SklaeyM, BenaroshD, CynamonM. In vitro activities of omadacycline against rapidly growing mycobacteria [abstract #5]. In: Program and abstracts of the ESCMID\/ASM Conference on Drug Development(Lisbon, Portugal). 2018.","DOI":"10.1128\/AAC.02522-18"},{"key":"2019081601553266800_CIT0012","article-title":"Meeting of the Antimicrobial Drugs Advisory Committee","author":"Food and Drug Administration"},{"key":"2019081601553266800_CIT0013","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","article-title":"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline","volume":"47","author":"Flarakos","year":"2017","journal-title":"Xenobiotica"},{"key":"2019081601553266800_CIT0014","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1128\/AAC.01393-16","article-title":"Randomized, open-label study of the pharmacokinetics and safety of oral and intravenous administration of omadacycline to healthy subjects","volume":"60","author":"Sun","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0015","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01487-17","article-title":"Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens","volume":"62","author":"Bundrant","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0016","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/phar.2185","article-title":"Omadacycline enters the ring: a new antimicrobial contender","volume":"38","author":"Barber","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2019081601553266800_CIT0017","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00003088-198815060-00001","article-title":"Clinical pharmacokinetics of doxycycline and minocycline","volume":"15","author":"Saivin","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"2019081601553266800_CIT0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0019","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"2019081601553266800_CIT0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02057-17","article-title":"Pharmacokinetics and safety of omadacycline in subjects with impaired renal function","volume":"62","author":"Berg","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0021","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/jcph.814","article-title":"Effect of food on the bioavailability of omadacycline in healthy participants","volume":"57","author":"Tzanis","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2019081601553266800_CIT0022","article-title":"Prescribing information.","author":"Nuzyra"},{"key":"2019081601553266800_CIT0023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02368-16","article-title":"In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0024","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O\u2019Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"2019081601553266800_CIT0025","unstructured":"O\u2019Riordan WA , GreenS, OvercashJS, et al Efficacy of oral and IV omadacycline vs. linezolid for treating adult individuals with ABSSSI: analysis by infection type and pathogen in the OASIS study [poster 1252]. In: Program and abstracts of the 27th European Congress of Clinical Microbiology and Infectious Diseases (Vienna, Austria). 2017."},{"key":"2019081601553266800_CIT0026","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx163.1364","article-title":"Efficacy and safety of omadacycline in chronic kidney disease patients with acute bacterial skin and skin structure infections: a subgroup analysis from the OASIS trial [","volume-title":"IDWeek 2017","author":"File","year":"2017"},{"key":"2019081601553266800_CIT0027","article-title":"Efficacy and safety of omadacycline in chronic kidney disease patients with acute bacterial skin and skin structure infections and high body mass index or diabetes: a subgroup analysis from the OASIS trial [","volume-title":"IDWeek 2017","author":"Wilcox","year":"2017"},{"key":"2019081601553266800_CIT0028","article-title":"Efficacy and safety of omadacycline in intravenous drug using and hepatitis c-positive patients with acute bacterial skin and skin structure infections: a subgroup analysis from the OASIS trial [poster 1885].","author":"Ohl","year":"2017"},{"key":"2019081601553266800_CIT0029","author":"Paratek Parmaceuticals"},{"key":"2019081601553266800_CIT0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"2019081601553266800_CIT0031","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2017.10.010","article-title":"Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014)","volume":"90","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019081601553266800_CIT0032","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diagmicrobio.2018.01.019","article-title":"Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014)","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019081601553266800_CIT0033","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"58","author":"Macone","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0034","volume-title":"Pharmacokinetics and safety of omadacycline in patients with uncomplicated urinary tract infections. ASM Microbe 2017","author":"Overcash"},{"key":"2019081601553266800_CIT0035","first-page":"e01784","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-omadacycline in rats","volume":"61","author":"Lin","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0036","doi-asserted-by":"crossref","unstructured":"Kim O , LeahyR, TraczewskiM, MaconeA, SteenbergenJ, TanakaK. Activity and efficacy of omadacycline against Clostridium difficile [poster 1325]. In: Program and abstracts of the 26th European Congress on Clinical Microbiology and Infectious Disease (Amsterdam, The Netherlands). 2016.","DOI":"10.26226\/morressier.56d6be7ad462b80296c97dee"},{"key":"2019081601553266800_CIT0037","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/cix833","article-title":"Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and metaanalysis","volume":"66","author":"Tariq","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019081601553266800_CIT0038","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1128\/AAC.00948-12","article-title":"A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections","volume":"56","author":"Noel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2019081601553266800_CIT0039","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01581-18","article-title":"Omadacycline gut microbiome exposure does not induce Clostridium difficile proliferation or toxin production in a model that simulates the proximal, medial and distal human colon","volume":"63","author":"Moura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2019081601553266800_CIT0040","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1128\/AAC.00320-16","article-title":"In vitro and in vivo assessments of cardiovascular effects with omadacycline","volume":"60","author":"Tanaka","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/5\/890\/29169439\/ciz242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:29:52Z","timestamp":1663115392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/5\/890\/5409710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,20]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,3,20]]},"published-print":{"date-parts":[[2019,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz242","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9,1]]},"published":{"date-parts":[[2019,3,20]]}}}